Market Newsdesk

First Trust Energy Income and Growth Fund Declares its Quarterly Distribution of $0.30 Per Share

WHEATON, Ill.–(BUSINESS WIRE)–
First Trust Energy Income and Growth Fund (the “Fund”) (NYSE American: FEN) has declared the Fund’s regularly scheduled quarterly distribution of $0.30 per share. The distribution will be payable on January 29, 2021, to shareholders of record as of January 25, 2021. The ex-dividend date is expected to be January 22, 2021. The quarterly distribution information for the Fund appears below.

First Trust Energy Income and Growth Fund (FEN):

Distribution per share:		$0.30
Distribution Rate based on the January 8, 2021 NAV of $13.18:		9.10%
Distribution Rate based on the January 8, 2021 closing market price of $11.56:		10.38%

It is anticipated that, due to the tax treatment of cash distributions made by the publicly-traded master limited partnerships (“MLPs”) in which the Fund invests, a portion of distributions the Fund makes to Common Shareholders may consist of a tax-deferred return of capital. The final determination of the source and tax status of all distributions paid in 2021 will be made after the end of 2021 and will be provided on Form 1099-DIV.

The Fund is a non-diversified, closed-end management investment company that seeks a high level of after-tax total return with an emphasis on current distributions paid to shareholders. The Fund focuses on investing in MLPs and related public entities in the energy sector which the Fund’s investment sub-advisor believes offer opportunities for income and growth. The Fund is treated as a regular corporation, or a “C” corporation, for United States federal income tax purposes and, as a result, is subject to corporate income tax to the extent the Fund recognizes taxable income.

First Trust Advisors L.P. (“FTA”) is a federally registered investment advisor and serves as the Fund’s investment advisor. FTA and its affiliate First Trust Portfolios L.P. (“FTP”), a FINRA registered broker-dealer, are privately-held companies that provide a variety of investment services. FTA has collective assets under management or supervision of approximately $171 billion as of December 31, 2020 through unit investment trusts, exchange-traded funds, closed-end funds, mutual funds and separate managed accounts. FTA is the supervisor of the First Trust unit investment trusts, while FTP is the sponsor. FTP is also a distributor of mutual fund shares and exchange-traded fund creation units. FTA and FTP are based in Wheaton, Illinois.

Energy Income Partners, LLC (“EIP”) serves as the Fund’s investment sub-advisor and provides advisory services to a number of investment companies and partnerships for the purpose of investing in MLPs and other energy infrastructure securities. EIP is one of the early investment advisors specializing in this area. As of December 31, 2020, EIP managed or supervised approximately $3.8 billion in client assets.

Past performance is no assurance of future results. Investment return and market value of an investment in the Fund will fluctuate. Shares, when sold, may be worth more or less than their original cost. There can be no assurance that the Fund’s investment objectives will be achieved. The Fund may not be appropriate for all investors.

Principal Risk Factors: The Fund is subject to risks, including the fact that it is a non-diversified closed-end management investment company.

Securities held by a fund, as well as shares of a fund itself, are subject to market fluctuations caused by factors such as general economic conditions, political events, regulatory or market developments, changes in interest rates and perceived trends in securities prices. Shares of a fund could decline in value or underperform other investments as a result of the risk of loss associated with these market fluctuations. In addition, local, regional or global events such as war, acts of terrorism, spread of infectious diseases or other public health issues, recessions, or other events could have a significant negative impact on a fund and its investments. Such events may affect certain geographic regions, countries, sectors and industries more significantly than others. The outbreak of the respiratory disease designated as COVID-19 in December 2019 has caused significant volatility and declines in global financial markets, which have caused losses for investors. The impact of this COVID-19 pandemic may last for an extended period of time and will continue to impact the economy for the foreseeable future.

Because the Fund is concentrated in securities issued by energy companies, energy sector MLPs and MLP-related entities, it will be more susceptible to adverse economic or regulatory occurrences affecting those industries, including high interest costs, high leverage costs, the effects of economic slowdown, surplus capacity, increased competition, uncertainties concerning the availability of fuel at reasonable prices, the effects of energy conservation policies and other factors.

The Fund’s use of derivatives may result in losses greater than if they had not been used, may require the fund to sell or purchase portfolio securities at inopportune times, may limit the amount of appreciation the Fund can realize on an investment, or may cause the fund to hold a security that it might otherwise sell.

Investment in non-U.S. securities is subject to the risk of currency fluctuations and to economic and political risks associated with such foreign countries.

Use of leverage can result in additional risk and cost, and can magnify the effect of any losses.

The risks of investing in the fund are spelled out in the shareholder report and other regulatory filings.

The information presented is not intended to constitute an investment recommendation for, or advice to, any specific person. By providing this information, First Trust is not undertaking to give advice in any fiduciary capacity within the meaning of ERISA, the Internal Revenue Code or any other regulatory framework. Financial professionals are responsible for evaluating investment risks independently and for exercising independent judgment in determining whether investments are appropriate for their clients.

The Fund’s daily closing NYSE American price and net asset value per share as well as other information can be found at www.ftportfolios.com or by calling 1-800-988-5891.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210111006036/en/

Press Inquiries Jane Doyle 630-765-8775

Analyst Inquiries Jeff Margolin 630-915-6784

Broker Inquiries Jeff Margolin 630-915-6784

KEYWORDS: Illinois United States North America

INDUSTRY KEYWORDS: Professional Services Finance

MEDIA:

Logo

Atlantic Broadband Launches WiFi Your Way™, Powered by Plume HomePass^®

Next generation technology delivers phenomenal in-home WiFi experience

QUINCY, Mass.–(BUSINESS WIRE)–Atlantic Broadband, the eighth-largest cable operator in the U.S., today announced that it has launched WiFi Your Way^TM, a best-in-class managed home WiFi solution powered by Plume HomePass^® that will provide expanded WiFi coverage with enhanced reliability and superfast speed in every area of the home.

The new service, which uses Plume’s cloud-based artificial intelligence (AI) technology and is accessed via the WiFi Your Way App, features:

• Adapt^TMcontinually learns and self-optimizes proactively to deliver greater speed and coverage throughout the home.
• Control^TMprovides intuitive tools for personalization, allowing the user to set guest and child access controls (including age-appropriate content filters).
• Speed Test capabilities are built-in so customers can easily monitor internet speed and performance.
• Guard^TM provides best-in-class online security powered by AI that detects and protects in real time. The system halts suspicious activity, blocks ad and malware and quarantines any compromised devices.
• Sense^TM uses WiFi-connected devices to provide whole-home motion awareness in real time for peace of mind and among many use-cases, provides alerts if there is motion when a customer is out of the home.

The WiFi Your Way App (for iOS and Android devices) guides customers through an easy self-installation of SuperPods, which plug into a wall outlet to provide superfast whole-home coverage. The SuperPods work with any Atlantic Broadband gateway or modem. Customers lease the SuperPods rather than purchase them, keeping upfront costs down for customers.

“Home WiFi is the way customers most commonly experience our internet service, so it must be the best it can be,” said Heather McCallion, Vice President of Products and Programming for Atlantic Broadband. “As in-home WiFi becomes increasingly important to our customers, their in-home networks must be reliable, fast and deliver the connectivity they need to work and learn from home. Now, through our partnership with Plume, Atlantic Broadband’s high-capacity, fiber-rich network will be joined with a powerful in-home network to deliver a phenomenal WiFi experience with wall-to-wall coverage, personalized controls and superfast speeds up to 1 Gig.”

“Plume is thrilled to enable Atlantic Broadband to deliver an unparalleled in home experience by providing access to an expanded and highly personalized managed WiFi experience featuring high-speed connectivity, parental controls and guest access, tightly secured devices and more,” said Tyson Marian, Chief Commercial Officer at Plume. “Now more than ever subscribers need access to an expanded set of in-home experiences to enrich their daily lives––by rolling out WiFi Your Way powered by Plume HomePass, Atlantic Broadband has introduced a powerful solution to meet the needs of the ever-changing smart home.”

To learn more about the WiFi Your Way solution powered by Plume HomePass, visit https://atlanticbb.com/support/wifiyourway. To learn about Atlantic Broadband’s Internet, phone and TV offerings for business, visit atlanticbb.com/business.

ABOUT ATLANTIC BROADBAND

Atlantic Broadband, a subsidiary of Cogeco Communications Inc. (TSX: CCA), is the eighth largest cable operator in the United States, based on the number of television service customers served. The company provides its residential and business customers with Internet, TV and Phone services in 11 states: Connecticut, Delaware, Florida, Maine, Maryland, New Hampshire, New York, Pennsylvania, South Carolina, Virginia and West Virginia. Atlantic Broadband is headquartered in Quincy, Massachusetts. WiFi Your Way is a registered trademark of Atlantic Broadband.

ABOUT PLUME^®

Plume is the creator of the world’s first Consumer Experience Management (CEM) Platform, powered by OpenSync™, which enables the curation and delivery of new Smart Home Services rapidly and at massive scale. The Plume HomePass™ Smart Home Services Suite which includes Plume Adapt™, Guard™, Control™, and Sense™ is managed by the Plume Cloud, a data- and AI-driven cloud controller currently running the largest software-defined network in the world. Plume leverages OpenSync, an open-source framework which comes pre-integrated and supported on the leading silicon and platform SDKs for coordination by the Plume Cloud. Visit www.plume.com and www.opensync.io.

Plume, Powered by Plume HomePass, OpenSync, HomePass, Haystack, SuperPod, Adapt, Guard, Control, and Sense are either trademarks or registered trademarks of Plume Design, Inc. Other company and product names are used for informational purposes only and may be trademarks of their respective owners.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210111006033/en/

Media

Andrew Walton

Atlantic Broadband

617.786.8800 x102

[email protected]

[email protected]

Andrew Laszacs

Bob Gold & Associates for Plume

+1 310.940.4458

[email protected]

KEYWORDS: Massachusetts United States North America

INDUSTRY KEYWORDS: VoIP Software Mobile/Wireless Networks Internet Data Management Technology Semiconductor Security Satellite Audio/Video Telecommunications

MEDIA:

Logo

Fluor Awarded Reimbursable Services Contract for North America’s First Small Modular Nuclear Reactor Project by Utah Associated Municipal Power Systems (UAMPS)

Fluor’s NuScale Power also signs development cost reimbursement agreement with UAMPS

IRVING, Texas–(BUSINESS WIRE)–Fluor Corporation (NYSE: FLR) announced today that Utah Associated Municipal Power Systems (UAMPS) awarded the company a cost-reimbursable development agreement to provide estimating, development, design and engineering services for its Carbon-Free Power Project. Fluor will book the initial undisclosed value in the first quarter of 2021 and as it accrues.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210111006008/en/

“Fluor’s development agreement with UAMPS for its Carbon-Free Power Project is a monumental milestone toward providing clean load following, base load energy for UAMPS members using NuScale Power’s unique small modular reactor design,” said Alan Boeckmann, executive chairman of Fluor. “Fluor has been a preeminent player in the nuclear industry for 70 years and is well positioned to assist UAMPS and the DOE to accomplish their objectives to provide carbon-free energy for its customers and to deploy a commercially viable small modular reactor with safety, security and performance characteristics that exceed the operational capabilities of current certified designs.”

The U.S. Department of Energy (DOE) recently provided UAMPS a multi-year cost-share award for up to $1.355 billion in funding, subject to future year appropriations, to aid in the development of the first small modular nuclear reactor project in the U.S. The DOE funding is intended to mitigate licensing and financial risk and to accelerate commercial deployment schedules in order to meet critical U.S. energy, environment and economic goals.

Fluor has been serving the nuclear industry for more than 70 years including the design and construction support for more than 25 nuclear plants, plus nearly 100 million hours of nuclear operations and maintenance work. Fluor also provides the following nuclear industry services: decontamination and decommissioning, emergency response and recovery, environmental remediation, laboratory management, national security, nuclear power plant support services, site closure management and waste management.

About Fluor Corporation

Fluor Corporation (NYSE: FLR) is a global engineering, procurement, fabrication, construction and maintenance company with projects and offices on six continents. Fluor’s 45,000 employees build a better world and provide sustainable solutions by designing, building and maintaining safe, well executed projects. Fluor had revenue of $17.3 billion in 2019 and is ranked 181 among the Fortune 500 companies. With headquarters in Irving, Texas, Fluor has served its clients for more than 100 years. For more information, please visit www.fluor.com or follow Fluor on Twitter, LinkedIn, Facebook and YouTube.

#corp

View source version on businesswire.com: https://www.businesswire.com/news/home/20210111006008/en/

Brian Mershon

Global Media Relations

864.281.6484

Jason Landkamer

Investor Relations

469.398.7222

KEYWORDS: Utah Texas United States North America

INDUSTRY KEYWORDS: Engineering Manufacturing Commercial Building & Real Estate Energy Construction & Property Building Systems Nuclear

MEDIA:

Logo

Photo

A futuristic rendering of the NuScale Power plant (Photo: Business Wire)

Acorda Therapeutics to Present at H.C. Wainwright BIOCONNECT Virtual Conference

ARDSLEY, N.Y.–(BUSINESS WIRE)–
Acorda Therapeutics, Inc. (NASDAQ: ACOR) announced that Ron Cohen, M.D., President and Chief Executive Officer, will present during the January 11^th -14^th H.C. Wainwright BIOCONNECT Virtual Conference. An audio webcast of the presentation can be accessed under “Investor Events” in the Investor section of the Acorda website at www.acorda.com.

For more information about the conference, please visit the event website at www.hcwevents.com/bioconnect.

About Acorda Therapeutics

Acorda Therapeutics develops therapies to restore function and improve the lives of people with neurological disorders. INBRIJA® (levodopa inhalation powder) is approved for intermittent treatment of OFF episodes in adults with Parkinson’s disease treated with carbidopa/levodopa. INBRIJA is not to be used by patients who take or have taken a nonselective monoamine oxidase inhibitor such as phenelzine or tranylcypromine within the last two weeks. INBRIJA utilizes Acorda’s innovative ARCUS® pulmonary delivery system, a technology platform designed to deliver medication through inhalation. Acorda also markets the branded AMPYRA® (dalfampridine) Extended Release Tablets, 10 mg.

Forward-Looking Statements

This press release includes forward-looking statements. All statements, other than statements of historical facts, regarding management’s expectations, beliefs, goals, plans or prospects should be considered forward-looking. These statements are subject to risks and uncertainties that could cause actual results to differ materially, including: we may not be able to successfully market INBRIJA or any other products under development; the COVID-19 pandemic, including related quarantines and travel restrictions, and the potential for the illness to affect our employees or consultants or those that work for other companies we rely upon, could have a material adverse effect on our business operations or product sales; our ability to raise additional funds to finance our operations, repay outstanding indebtedness or satisfy other obligations, and our ability to control our costs or reduce planned expenditures and take other actions which are necessary for us to continue as a going concern; risks associated with the trading of our common stock and our reverse stock split; risks associated with complex, regulated manufacturing processes for pharmaceuticals, which could affect whether we have sufficient commercial supply of INBRIJA to meet market demand; third party payers (including governmental agencies) may not reimburse for the use of INBRIJA or our other products at acceptable rates or at all and may impose restrictive prior authorization requirements that limit or block prescriptions; competition for INBRIJA, AMPYRA and other products we may develop and market in the future, including increasing competition and accompanying loss of revenues in the U.S. from generic versions of AMPYRA (dalfampridine) following our loss of patent exclusivity; the ability to realize the benefits anticipated from acquisitions, among other reasons because acquired development programs are generally subject to all the risks inherent in the drug development process and our knowledge of the risks specifically relevant to acquired programs generally improves over time; the risk of unfavorable results from future studies of INBRIJA (levodopa inhalation powder) or from our other research and development programs, or any other acquired or in-licensed programs ; the occurrence of adverse safety events with our products; the outcome (by judgment or settlement) and costs of legal, administrative or regulatory proceedings, investigations or inspections, including, without limitation, collective, representative or class action litigation; failure to protect our intellectual property, to defend against the intellectual property claims of others or to obtain third party intellectual property licenses needed for the commercialization of our products; and failure to comply with regulatory requirements could result in adverse action by regulatory agencies. These and other risks are described in greater detail in our filings with the Securities and Exchange Commission. We may not actually achieve the goals or plans described in our forward-looking statements, and investors should not place undue reliance on these statements. Forward-looking statements made in this press release are made only as of the date hereof, and we disclaim any intent or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210111006030/en/

Tierney Saccavino

(917) 783-0251

[email protected]

KEYWORDS: New York United States North America

INDUSTRY KEYWORDS: Biotechnology General Health Pharmaceutical Health

MEDIA:

Logo